Putnam FL Investment Management Co. boosted its stake in shares of Eli Lilly And Co (NYSE:LLY) by 545.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,069 shares of the company’s stock after purchasing an additional 12,734 shares during the quarter. Putnam FL Investment Management Co.’s holdings in Eli Lilly And Co were worth $1,744,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Athena Capital Advisors LLC acquired a new stake in shares of Eli Lilly And Co in the 4th quarter valued at about $26,000. Wakefield Asset Management LLLP acquired a new stake in shares of Eli Lilly And Co in the 4th quarter valued at about $27,000. Larson Financial Group LLC acquired a new stake in shares of Eli Lilly And Co in the 4th quarter valued at about $29,000. Ironwood Financial llc acquired a new stake in shares of Eli Lilly And Co in the 4th quarter valued at about $30,000. Finally, Acima Private Wealth LLC acquired a new stake in shares of Eli Lilly And Co in the 4th quarter valued at about $33,000. Institutional investors own 79.58% of the company’s stock.
A number of analysts recently issued reports on the company. Bank of America set a $129.00 target price on Eli Lilly And Co and gave the company a “hold” rating in a research report on Thursday, March 21st. Citigroup set a $124.00 target price on Eli Lilly And Co and gave the company a “hold” rating in a research report on Tuesday, February 26th. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $121.00 price objective for the company in a research note on Wednesday, December 19th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. Finally, Argus reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research note on Thursday, December 27th. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Eli Lilly And Co currently has a consensus rating of “Buy” and an average target price of $115.68.
LLY opened at $129.05 on Tuesday. The company has a quick ratio of 1.38, a current ratio of 1.73 and a debt-to-equity ratio of 1.07. The company has a market cap of $133.67 billion, a price-to-earnings ratio of 23.25, a P/E/G ratio of 2.46 and a beta of 0.33. Eli Lilly And Co has a 52 week low of $75.40 and a 52 week high of $132.13.
Eli Lilly And Co (NYSE:LLY) last issued its earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). The business had revenue of $6.44 billion for the quarter, compared to analysts’ expectations of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the company posted $1.14 earnings per share. On average, equities research analysts expect that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Putnam FL Investment Management Co. Buys 12,734 Shares of Eli Lilly And Co (LLY)” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2019/04/02/putnam-fl-investment-management-co-buys-12734-shares-of-eli-lilly-and-co-lly.html.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: What are catch-up contributions?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.